J Korean Diabetes.  2022 Mar;23(1):21-27. 10.4093/jkd.2022.23.1.21.

Blood Pressure Variability and Diabetes Mellitus

• Jeong C
• Sohn TS

• KMID: 2528407
• DOI: http://doi.org/10.4093/jkd.2022.23.1.21

Abstract

Increased blood pressure variability (BPV) has been found to significantly increase the risk of cardiovascular morbidity and mortality in the non-diabetic population. The prognostic importance of increased BPV for the development of micro- and macrovascular complications in type 2 diabetes has been investigated. Type 2 diabetes can increase BPV through different mechanisms, including increased arterial stiffness and autonomic dysfunction. Several studies in type 2 diabetic patients showed inconclusive results regarding all-cause mortality, microvascular complication, and extended major adverse cardiovascular events (MACE). However, some trials showed that BPV might be regarded as a potentially important therapeutic target in the management of type 2 diabetes regarding MACE. For now, the primary goal of antihypertensive treatment in patients with type 2 diabetes shall remain to controll mean blood pressure levels. However, when future studies show consistent results, BPV might be regarded as a therapeutic target in type 2 diabetic patients.

Keyword

Blood pressure; Cause of death; Diabetes complications; Diabetes mellitus; type 2

Reference

1.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998. 317:703–13. Erratum in: BMJ 1999;318:29.

2.Stamler J., Vaccaro O., Neaton JD., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993. 16:434–44.

3.McAlister FA., Lethebe BC., Lambe C., Williamson T., Lowerison M. Control of glycemia and blood pressure in British adults with diabetes mellitus and subsequent ther-apy choices: a comparison across health states. Cardiovasc Diabetol. 2018. 17:27.

4.Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl. 2003. 21:S25–30.

5.Hansson L., Zanchetti A., Carruthers SG., Dahlöf B., Elm-feldt D., Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998. 351:1755–62.

6.Rothwell PM., Howard SC., Dolan E., O'Brien E., Dobson JE., Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010. 375:895–905.

7.Mehlum MH., Liest⊘l K., Kjeldsen SE., Julius S., Hua TA., Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 2018. 39:2243–51.

8.Stevens SL., Wood S., Koshiaris C., Law K., Glasziou P., Stevens RJ, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ. 2016. 354:i4098.

9.Wu C., Shlipak MG., Stawski RS., Peralta CA., Psaty BM., Harris TB, et al. Visit-to-visit blood pressure variability and mortality and cardiovascular outcomes among older adults: the Health, Aging, and Body Composition Study. Am J Hypertens. 2017. 30:151–8.

10.Imai Y., Aihara A., Ohkubo T., Nagai K., Tsuji I., Minami N, et al. Factors that affect blood pressure variability. A com-munity-based study in Ohasama, Japan. Am J Hypertens. 1997. 10:1281–9.

11.Sethi BK., Baruah MP., Kumar AS. Blood pressure variability in patients with diabetes mellitus with hypertension: treatment recommendations and role of amlodipine. J Assoc Physicians India. 2017. 65:67–71.

12.Spallone V. Blood pressure variability and autonomic dysfunction. Curr Diab Rep. 2018. 18:137.

13.Weston KS., Sacre JW., Jellis CL., Coombes JS. Contribution of autonomic dysfunction to abnormal exercise blood pressure in type 2 diabetes mellitus. J Sci Med Sport. 2013. 16:8–12.

14.Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010. 55:1318–27.

15.Prenner SB., Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis. 2015. 238:370–9.

16.Ben-Shlomo Y., Spears M., Boustred C., May M., Anderson SG., Benjamin EJ, et al. Aortic pulse wave velocity im-proves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014. 63:636–46.

17.Hata J., Arima H., Rothwell PM., Woodward M., Zoungas S., Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013. 128:1325–34.

18.Zoppini G., Verlato G., Targher G., Bonora E., Trombetta M., Muggeo M. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Metab Res Rev. 2008. 24:624–8.

19.Yu ZB., Wang JB., Li D., Chen XY., Lin HB., Chen K. Prognostic value of visit-to-visit systolic blood pressure variability related to diabetic kidney disease among patients with type 2 diabetes. J Hypertens. 2019. 37:1411–8.

20.Wan EY., Fung CS., Yu EY., Fong DY., Chen JY., Lam CL. Association of visit-to-visit variability of systolic blood pressure with cardiovascular disease and mortality in primary care Chinese patients with type 2 diabetes-a retrospective population-based cohort study. Diabetes Care. 2017. 40:270–9.

21.Viazzi F., Bonino B., Mirijello A., Fioretto P., Giorda C., Ce-riello A, et al. Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. J Hypertens. 2019. 37:805–13. Erratum in: J Hypertens 2020;38:980.

22.Takao T., Suka M., Yanagisawa H., Matsuyama Y., Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbu-minuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract. 2017. 128:15–23.

23.Takao T., Matsuyama Y., Yanagisawa H., Kikuchi M., Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. J Diabetes Complications. 2014. 28:185–90.

24.Sohn MW., Epstein N., Huang ES., Huo Z., Emanuele N., Stukenborg G, et al. Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. J Diabetes Complications. 2017. 31:195–201.

25.Okada H., Fukui M., Tanaka M., Matsumoto S., Mineoka Y., Nakanishi N, et al. Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013. 36:1908–12.

26.McMullan CJ., Lambers Heerspink HJ., Parving HH., Dw-yer JP., Forman JP., de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis. 2014. 64:714–22.

27.Bell KJL., Azizi L., Nilsson PM., Hayen A., Irwig L., Östgren CJ, et al. Prognostic impact of systolic blood pressure variability in people with diabetes. PLoS One. 2018. 13:e0194084. Erratum in: PLoS One 2019;14:e0224538.

28.Hsieh YT., Tu ST., Cho TJ., Chang SJ., Chen JF., Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5·5-year prospective analysis. Eur J Clin Invest. 2012. 42:245–53.

29.Ohkuma T., Woodward M., Jun M., Muntner P., Hata J., Co-lagiuri S, et al. Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: the ADVANCE-ON study. Hypertension. 2017. 70:461–8.

30.Cardoso CRL., Leite NC., Salles GF. Prognostic importance of visit-to-visit blood pressure variability for microand macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2020. 19:50.

31.Chiriacò M., Pateras K., Virdis A., Charakida M., Kyriako-poulou D., Nannipieri M, et al. Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019. 21:2587–98.

32.Noshad S., Mousavizadeh M., Mozafari M., Nakhjavani M., Esteghamati A. Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes. J Hum Hypertens. 2014. 28:37–43.

33.Rizzoni D., Muiesan ML., Porteri E., Salvetti M., Castellano M., Bettoni G, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol. 1998. 32:985–92.

34.Rizzoni D., Agabiti-Rosei C., Agabiti-Rosei E. Hemody-namic consequences of changes in microvascular structure. Am J Hypertens. 2017. 30:939–46.

35.Flynn MD., Tooke JE. Diabetic neuropathy and the micro-circulation. Diabet Med. 1995. 12:298–301.

36.De Vriese AS., Verbeuren TJ., Van de Voorde J., Lameire NH., Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000. 130:963–74.

37.Zhou TL., Henry RMA., Stehouwer CDA., van Sloten TT., Reesink KD., Kroon AA. Blood pressure variability, arterial stiffness, and arterial remodeling. Hypertension. 2018. 72:1002–10.

38.Nichols WW., Nicolini FA., Pepine CJ. Determinants of isolated systolic hypertension in the elderly. J Hypertens Suppl. 1992. 10:S73–7.

39.Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996. 275:1571–6.

40.Lim SS., Vos T., Flaxman AD., Danaei G., Shibuya K., Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012. 380:2224–60. Erratum in: Lancet 2013, 381, 1276 Erratum in: Lancet 2013;381:628.

41.Vasan RS., Larson MG., Leip EP., Evans JC., O'Donnell CJ., Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001. 345:1291–7.

42.Parati G., Ochoa JE., Salvi P., Lombardi C., Bilo G. Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care. 2013. 36(Suppl 2):S312–24.

43.Parati G., Ochoa JE., Lombardi C., Bilo G. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep. 2015. 17:537.

44.Veloudi P., Sharman JE. Methodological factors affecting quantification of blood pressure variability: a scoping review. J Hypertens. 2018. 36:711–9.

45.Wang J., Shi X., Ma C., Zheng H., Xiao J., Bian H, et al. Vis-it-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2017. 35:10–7.